We are excited to announce that our Principal, Ms. Pauli Wong, has been appointed as the Honorary IP Advisor by the Hong Kong Medical & Healthcare Device Industries Association (HKMHDIA) for the term 2025-2026. She will provide advice and guidance to support HKMHDIA’s mission in advocating for streamlined regulatory policies to position Hong Kong as a leader in medical technologies. 

Pauli has served many HKMHDIA members in the life sciences and medical devices sectors as their patent attorney over the past few years. She is eager to provide strategic guidance for the association, leveraging her deep understanding of intellectual property to help HKMHDIA members safeguard their innovations and enhance their competitive edge. 

We are confident that Pauli's expertise and dedication will greatly benefit HKMHDIA and its members, driving innovation and success in the life sciences and medical devices sector of Hong Kong. 

我們過去活動

Recommended Insights

CN1982128B Figure

2019 CHINA TOP 10 IP CASE: VALEO V. LUCAS, FUKE, & CHEN

2020年6月8日
Every year in the spring The Supreme People’s Court of PRC announces its “Top 10 Intellectual Property (IP) cases” and “50 typical IP cases in Chinese courts” of the year. Although not having precedential weight, these cases serve as a reference and guide people's courts at all levels regarding their intellectual property trials. It’s always […]

Amendments to the China Patent Examination Guidelines in 2022 - Part 1: New rules for designs in view of China signing onto the Hague Agreement

2022年12月2日
This year, China stepped further onto the international scene by signing on as a member of the Hague Agreement. The Hague Agreement is an international registration system allowing applicants to file a single international design application in a single language to obtain protection in over 100 designated member countries. The US has been a member […]

China Releases Draft Examination Guidelines for the new Patent Law

2020年12月4日
The Chinese Patent Office (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but not limited […]

Compositions Limited by Use: A Cautionary Tale

2022年10月26日
Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]
Top crossarrow-right